Watertown Pharmaceutical Company to Pay Nearly $4.7 Million to Resolve False Claims Act Allegations

BOSTON – EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc. (EyePoint), has agreed to pay $4,678,981 to resolve allegations that it paid kickbacks to Ambulatory Surgery Centers (ASCs) to induce the ASCs to purchase its drug, DEXYCU. This scheme, the government alleges, violated the Anti-Kickback Statute and the False Claims Act. 

Source: U.S. Department of Justice